<DOC>
	<DOC>NCT01247493</DOC>
	<brief_summary>A phase II clinical trial evaluating the efficacy and tolerability of induction and consolidation chemotherapy comprising Fludarabine, cytarabine and attenuated-dose Idarubicin (modified-FLAI) in the elderly patients with acute myeloid leukemia.</brief_summary>
	<brief_title>Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>previously untreated AML (excluding acute promyelocytic leukemia) age greater than 60 years old ECOG PS (Eastern Cooperative Oncology Group Performance scale) less than 2 adequate hepatic/ renal/ cardiac function acute promyelocytic leukemia significant cardiac disease combined nonhematologic malignancy aleukemic leukemia (only granulocytic sarcoma) CNS (Central Nervous system) involvement significant comorbidity/ uncontrollable bleeding tendency</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>fludarabine</keyword>
	<keyword>AML</keyword>
	<keyword>Efficacy</keyword>
	<keyword>tolerability</keyword>
</DOC>